Last reviewed · How we verify
SC10914
At a glance
| Generic name | SC10914 |
|---|---|
| Sponsor | Jiangxi Qingfeng Pharmaceutical Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study of SC10914 in Patients With gBRCA1/2 Mutation Advanced Ovarian Cancer (PHASE2)
- A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients (PHASE2)
- SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation (PHASE1, PHASE2)
- A Study of SC10914 in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SC10914 CI brief — competitive landscape report
- SC10914 updates RSS · CI watch RSS
- Jiangxi Qingfeng Pharmaceutical Co. Ltd. portfolio CI